Home > Healthcare > Drug Device Combination > Drug Filled Devices > Mucosal Atomization Device Market

Mucosal Atomization Device Market – Product Type (Nasal Atomization, Fiber Optic Atomization, Laryngo Tracheal Atomization, Bottle Atomizers), Technology (Gas Propelled Atomization, Electrical Atomization), End User – Global Forecast (2024 ­ 2032)

  • Report ID: GMI9181
  • Published Date: Apr 2024
  • Report Format: PDF

Mucosal Atomization Device Market Size

Mucosal Atomization Device Market size was valued at USD 712.3 million in 2023 growing at a CAGR of 7.4% between 2024 and 2032. The market growth is being fuelled by several key factors, including the rising prevalence of respiratory illnesses, expanding adoption of intranasal drug delivery systems, and a surging demand for safer and pain-free medication administration solution. Furthermore, the ease of handling and precise drug delivery facilitated by mucosal atomization devices are bolstering market expansion efforts.

Mucosal Atomization Device Market

With the increasing prevalence of respiratory conditions such as chronic sinusitis, allergic rhinitis, asthma, and respiratory infections, there is a growing need for effective delivery methods for respiratory medications. Mucosal atomization devices provide a targeted medication delivery method that directly applies the drugs to the respiratory mucosa, enhancing the treatment results for patients with respiratory conditions. According to a study published in National Library of Medicine in April 2022, prevalence of allergic rhinitis has increased globally since the 1990 affecting about 400 million people worldwide yearly.

Mucosal Atomization Device Market Trends

  • Continuous advancements in Mucosal Atomization Device (MAD) technology, including enhancements in atomization efficiency, device design, and materials, have positioned them as highly effective drug delivery solutions over conventional solutions such as nasal sprays, for treating challenging conditions like chronic sinusitis and allergic rhinitis.
  • Moreover, to overcome limited compatibility, the key focus of mucosal atomization device manufacturers can be observed in developing devices that are compatible with a wide array of medications, such as aqueous solutions, suspensions, and viscous drugs. Such enhancements in compatibility of mucosal atomization devices towards newer medications are expected to offer promising growth potential across new applications during the forecast period.

Mucosal Atomization Device Market Analysis

Mucosal Atomization Device Market, By Product Type, 2021 – 2032 (USD Million)

Based on the product type, the global mucosal atomization device market is classified into nasal atomization devices, fiber optic atomization devices, laryngo tracheal atomization devices, and bottle atomizers. The nasal atomization devices segment dominated the global market by securing a significant share of about 36.6% in 2023.

  • The dominance is propelled by increasing incidence of respiratory illness, capability of these devices to deliver drug efficiently in nasal mucosa, and growing applications of nasal atomization devices in pediatric and geriatric care. The nasal mucosa has rich blood supply and provides rapid absorption into the bloodstream. This facilities rapid and easy delivery of drugs, specifically during the treatment of respiratory illness.


Mucosal Atomization Device Market, By Technology (2023)

Based on the technology, the mucosal atomization device market is classified into gas propelled atomization devices and electrical atomization devices. The gas propelled atomization devices segment held the largest market share of 78.2% in 2023.

  • This dominance can be attributed to their ease of use, portability, cost effectiveness. Furthermore, in comparison to electrical atomization devices, the manufacturers face fewer regulatory hurdles in gas propelled mucosal atomization development and manufacturing.

Based on the end user, the mucosal atomization device market is classified into hospitals, ambulatory surgery centers, and speciality clinics. The hospital segment is expected to reach USD 606.2 million by the end of 2032.

  • Hospitals are expected to maintain their dominance in the market due to several key factors. Hospitals, with their diverse medical specialties and departments, including emergency medicine, anesthesia, critical care, otolaryngology, pediatrics, and others, provide a broad market for mucosal atomization devices. These devices are utilized across these specialties for various procedures, such as medication administration, pain management, anesthesia induction, and airway management, making hospitals a significant and varied market for mucosal atomization devices.


North America Mucosal Atomization Device Market, 2021 – 2032 (USD Million)

North America region is projected to maintain its dominance in the global mucosal atomization device market and is anticipated to reach USD 498.9 million by 2032.

  • North America has led the market, owing to several factors including presence of advanced healthcare facilities, growing demand for non-invasive drug delivery solutions, increasing incidence of respiratory illness, and growing focus towards patient centric model to enhance ease and comfort of the patients.
  • Moreover, the presence of key players such as Teleflex Inc., Becton, Dickinson & Company, and Cook Medical, Inc. among others in the region, that are focusing towards introducing new and innovative products to gain competitive edge, is also contributing towards significant growth of region in the market.

U.S. mucosal atomization device market was valued at USD 242.9 million in 2023.

  • Growing adoption of advanced nasal drug delivery systems and growing emphasis towards using safe and highly efficient drug delivery solutions is driving the growth of market.
  • Furthermore, increasing incidence of respiratory illness and availability of reimbursements on advanced treatment options is also supporting the market growth in U.S.

UK has emerged as a key player in the mucosal atomization device market in Europe, showcasing significant growth potential.

  • Growing demand for efficient and non-invasive drug delivery methods, increasing incidence of respiratory illness, and rising demand for precision drug delivery is driving the adoption of mucosal atomization devices in the country.
  • Moreover, UK's well developed health system supported by National Health Service (NHS) ensures widespread availability and utilization of medical devices, including mucosal atomization devices within the country.

China mucosal atomization device industry is anticipated to witness lucrative growth between 2024 – 2032. Increasing prevalence of respiratory illness, availability of low-cost mucosal atomization devices, and growing awareness towards safe and precision drug delivery options is fuelling the adoption of mucosal atomization devices in China.

Mucosal Atomization Device Market Share

The mucosal atomization device industry is moderately concentrated with the presence of few established market players. Strategic partnership and product enhancements are the key strategies being adopted by the market players to gain competitive edge over their rivals.

Mucosal Atomization Device Market Companies

Prominent players operating in the mucosal atomization device industry are as mentioned below:

  • Becton, Dickinson and Co.
  • BTME Group Ltd. (Medtree)
  • BVM Meditech Pvt. Ltd.
  • Cook Medical, Inc.
  • DeVilbiss Healthcare LLC
  • Intersurgical Ltd.
  • Kurve Therapeutics
  • Life-Assist Inc.
  • Medica Holdings, LLC
  • Medspray
  • Pulmodyne, Inc.
  • Teleflex Inc.

Mucosal Atomization Device Industry News:

  • In June 2021, Kurve Therapeutics announced a strategic partnership with Life Science Intelligence, to implement their Capital Planning Valuation Strategy. The partnership allowed Kurve Therapeutics to strategically plan for capital for the phase 3 clinical trials of their controlled particle dispersion intranasal drug delivery technology and to execute their go-to-market strategy.
  • In October 2021, Alcove Manufacturing and Distribution, Inc., and Pulmodyne, Inc. announced a strategic partnership aimed at broadening distribution, merging manufacturing capabilities, and advancing collaborative efforts in developing innovative mucosal atomization technologies. Under this agreement, Pulmodyne initiated the distribution of the EZ-Spray Atomization System through its established distribution channels.

The mucosal atomization device market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

  • Nasal atomization devices
  • Fiber optic atomization devices
  • Laryngo tracheal atomization devices
  • Bottle atomizers

Market, By Technology

  • Gas propelled atomization devices
  • Electrical atomization devices

Market, By End User

  • Hospitals
  • Ambulatory surgery centers
  • Specialty clinics

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada 
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • UAE
    • Saudi Arabia
    • Rest of Middle East and Afric


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Mucosal atomization device industry size recorded over USD 712.3 million in 2023 and is expected to depict 7.4% CAGR from 2024 to 2032, owing to the rising prevalence of respiratory illnesses, and the expanding adoption of intranasal drug delivery systems

The nasal atomization devices segment in the market accumulated 36.6% share in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, on account of the surging incidences of respiratory illness.

North America mucosal atomization device industry is projected to be worth USD 498.9 million by 2032, due to the robust presence of advanced healthcare facilities, high demand for non-invasive drug delivery solutions, and the increasing cases of respiratory illness.

Becton, Dickinson, and Co., BTME Group Ltd. (Medtree), BVM Meditech Pvt. Ltd., Cook Medical, Inc., DeVilbiss Healthcare LLC, Intersurgical Ltd., Kurve Therapeutics, Life-Assist Inc., Medica Holdings, LLC, Medspray, Pulmodyne, Inc., and Teleflex Inc. are some of the leading mucosal atomization device companies worldwide.

Mucosal Atomization Device Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 291
  • Countries covered: 22
  • Pages: 190
 Download Free Sample